Athira Pharma, Inc. — Director's Dealing 2022

Nov 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-10-28

Reporting Person: CHURCH KEVIN (Executive VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-28	Common Stock	M	3700	$1.35	Acquired	61395	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-28	Stock Option (Right to Buy)	$1.35	M	3700	Disposed	2028-12-17	Common Stock (3700)	Direct

Footnotes

F1: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.